Tuberculosis Clinical Trial
Official title:
A Phase IIa Specificity Trial of the Diagnostic Agent C-Tb, When Given Intradermally by the Mantoux Technique to Healthy Volunteers Previously Vaccinated With BCG
A new, more specific skin test to detect tuberculosis has been developed by Statens Serum
Institut in Denmark. The new skin test is named C-Tb and like the current Tuberculin a
positive test result will show as redness and/or swelling at the injection site, while a
negative test will leave no reactions.
The aim of this study is to test the C-Tb skin test in healthy adults previously BCG
vaccinated to determine if healthy non tuberculosis infected individuals has a truly
negative test result (this is called determining the specificity of the skin test). To be
able to compare the new skin test with the current Tuberculin skin test volunteers will be
injected with both the C-Tb and the TST skin test.
The trial is designed to investigate the specificity of C-Tb under various definitions of
cut-off in a double blind randomised, split-body study comparing 0.1 µg/0.1 mL C-Tb with the
reference agent 2 T.U. Tuberculin PPD RT23 SSI. (Each volunteer receives the C-Tb agent in
one arm and the 2 T.U. Tuberculin PPD in the other arm).
The C-Tb and 2 T.U. Tuberculin PPD agents are given concomitantly to each volunteer in the
RIGHT AND LEFT forearm according to a double blind randomisation scheme.
The primary objective of the trial is to assess the specificity of the C-Tb test as a
function of the cut-off value (i.e., the smallest size of induration measured in mm
resulting in a negative outcome of the C-Tb test) when the test is administered
intradermally by the Mantoux technique to healthy BCG vaccinated adults The specificity of
the C-Tb test is defined as the relative frequency of subjects in a healthy population
(i.e., no exposure to MTb) who have an induration response < cut-off after a C-Tb test.
Similarly the sensitivity is defined as the relative frequency of patients with an
induration response ≥ cut-off in TB patients.
An optimal cut-off point of being infected will be determined by combing the results from
the present specificity study with those from a parallel sensitivity study in patients
recently diagnosed with TB.
The secondary objectives of the trial are to compare the induration response of C-Tb with
the induration response of 2 T.U. Tuberculin PPD RT 23 SSI, to compare the induration
response of C-Tb with the in-vitro IFN-γ response measured at screening and 28 days after
the injections of the skin test agents using the QuantiFERON®-TB Gold In-Tube assay and
finally to record all adverse events occurring within 28 days after application of the
agents.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |